Brain-Gut Interactions in IBS

Jakub Fichna, Martin A Storr, Jakub Fichna, Martin A Storr

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with an estimated prevalence of 10-20%. Current understanding of the pathophysiology of IBS is incomplete due to the lack of a clearly identified pathological abnormality and due to the lack of reliable biomarkers. Possible mechanisms believed to contribute to IBS development and IBS like symptoms include physical stressors, such as infection or inflammation, psychological, and environmental factors, like anxiety, depression, and significant negative life events. Some of these mechanisms may involve the brain-gut axis (BGA). In this article we review the current knowledge on the possible involvement of the BGA in IBS and discuss new directions for potential future therapies of IBS.

Keywords: autonomic nervous system; brain-gut axis; hypothalamo-pituitary-adrenal axis; irritable bowel syndrome; pathophysiology.

References

    1. Adeyemo M. A., Spiegel B. M., Chang L. (2010). Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment. Pharmacol. Ther. 32, 738–75510.1111/j.1365-2036.2010.04409.x
    1. Aguilera G., Subburaju S., Young S., Chen J. (2008). The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 170, 29–3910.1016/S0079-6123(08)00403-2
    1. Akira S., Takeda K. (2004). Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–51110.1038/nri1391
    1. Arborelius L., Owens M. J., Plotsky P. M., Nemeroff C. B. (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1–1210.1677/joe.0.160R001
    1. Arebi N., Gurmany S., Bullas D., Hobson A., Stagg A., Kamm M. (2008). Review article: the psychoneuroimmunology of irritable bowel syndrome – an exploration of interactions between psychological, neurological and immunological observations. Aliment. Pharmacol. Ther. 28, 830–84010.1111/j.1365-2036.2008.03801.x
    1. Asagarasu A., Matsui T., Hayashi H., Tamaoki S., Yamauchi Y., Sato M. (2009). Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS). Chem. Pharm. Bull. 57, 34–4210.1248/cpb.57.34
    1. Atkinson W., Lockhart S., Whorwell P. J., Keevil B., Houghton L. A. (2006). Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130, 34–4310.1053/j.gastro.2005.09.031
    1. Atkinson W., Sheldon T. A., Shaath N., Whorwell P. J. (2004). Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 53, 1459–146410.1136/gut.2003.037697
    1. Azpiroz F. (2002). Gastrointestinal perception: pathophysiological implications. Neurogastroenterol. Motil. 14, 229–23910.1046/j.1365-2982.2002.00324.x
    1. Azpiroz F., Bouin M., Camilleri M., Mayer E. A., Poitras P., Serra J., Spiller R. C. (2007). Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol. Motil. 19(1 Suppl.), 62–8810.1111/j.1365-2982.2006.00875.x
    1. Bale T. L., Vale W. W. (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44, 525–55710.1146/annurev.pharmtox.44.101802.121410
    1. Bannerman D. M., Rawlins J. N., McHugh S. B., Deacon R. M., Yee B. K., Bast T., Zhang W. N., Pothuizen H. H., Feldon J. (2004). Regional dissociations within the hippocampus – memory and anxiety. Neurosci. Biobehav. Rev. 28, 273–28310.1016/j.neubiorev.2004.03.004
    1. Barbara G., Cremon C., De Giorgio R., Dothel G., Zecchi L., Bellacosa L., Carini G., Stanghellini V., Corinaldesi R. (2011). Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep. 13, 308–31510.1007/s11894-011-0195-7
    1. Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G. S., Santini D., Pasquinelli G., Morselli-Labate A. M., Grady E. F., Bunnett N. W., Collins S. M., Corinaldesi R. (2004). Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–70210.1053/j.gastro.2003.11.055
    1. Barnes N. M., Hales T. G., Lummis S. C., Peters J. A. (2009). The 5-HT3 receptor – the relationship between structure and function. Neuropharmacology 56, 273–28410.1016/j.neuropharm.2008.08.003
    1. Berman S., Munakata J., Naliboff B. D., Chang L., Mandelkern M., Silverman D., Kovalik E., Mayer E. A. (2000). Gender differences in regional brain response to visceral pressure in IBS patients. Eur. J. Pain 4, 157–17210.1053/eujp.2000.0167
    1. Berman S. M., Chang L., Suyenobu B., Derbyshire S. W., Stains J., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., Naliboff B. D., Mayer E. A. (2002). Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 123, 969–97710.1053/gast.2002.35990
    1. Blankstein U., Chen J., Diamant N. E., Davis K. D. (2010). Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 138, 1783–178910.1053/j.gastro.2009.12.043
    1. Bravo J. A., Dinan T. G., Cryan J. F. (2011). Alterations in the central CRF system of two different rat models of comorbid depression and functional gastrointestinal disorders. Int. J. Neuropsychopharmacol. 14, 666–68310.1017/S1461145710000994
    1. Brint E. K., MacSharry J., Fanning A., Shanahan F., Quigley E. M. (2011). Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am. J. Gastroenterol. 106, 329–33610.1038/ajg.2010.438
    1. Caldji C., Diorio J., Meaney M. J. (2000). Variations in maternal care in infancy regulate the development of stress reactivity. Biol. Psychiatry 48, 1164–117410.1016/S0006-3223(00)01084-2
    1. Camilleri M. (2011). LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol. Motil. 23, 193–20010.1111/j.1365-2982.2011.01749.x
    1. Camilleri M., Andresen V. (2009). Current and novel therapeutic options for irritable bowel syndrome management. Dig. Liver Dis. 41, 854–86210.1016/j.dld.2009.07.009
    1. Camilleri M., Choi M. G. (1997). Review article: irritable bowel syndrome. Aliment. Pharmacol. Ther. 11, 3–1510.1046/j.1365-2036.1997.84256000.x
    1. Camilleri M., Kerstens R., Rykx A., Vandeplassche L. (2008). A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358, 2344–235410.1056/NEJMoa0800670
    1. Carter D., Champney M., Hwang B., Eglen R. M. (1995). Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. Eur. J. Pharmacol. 280, 243–25010.1016/0014-2999(95)00195-Q
    1. Chang L., Mayer E. A., Labus J. S., Schmulson M., Lee O. Y., Olivas T. I., Stains J., Naliboff B. D. (2006). Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R277–R28410.1152/ajpregu.00729.2005
    1. Chang L., Sundaresh S., Elliott J., Anton P. A., Baldi P., Licudine A., Mayer M., Vuong T., Hirano M., Naliboff B. D., Ameen V. Z., Mayer E. A. (2009). Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol. Motil. 21, 149–15910.1111/j.1365-2982.2009.01328.x
    1. Chang L., Tong K., Ameen V. (2010). Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am. J. Gastroenterol. 105, 866–87510.1038/ajg.2010.49
    1. Chen J. Y., Blankstein U., Diamant N. E., Davis K. D. (2011). White matter abnormalities in irritable bowel syndrome and relation to individual factors. Brain Res. 1392, 121–13110.1016/j.brainres.2011.03.068
    1. Chey W. D., Maneerattaporn M., Saad R. (2011). Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 5, 253–26610.5009/gnl.2011.5.3.253
    1. Clarke G., Quigley E. M., Cryan J. F., Dinan T. G. (2009). Irritable bowel syndrome: towards biomarker identification. Trends Mol. Med. 15, 478–48910.1016/j.molmed.2009.08.001
    1. Coates M. D., Mahoney C. R., Linden D. R., Sampson J. E., Chen J., Blaszyk H., Crowell M. D., Sharkey K. A., Gershon M. D., Mawe G. M., Moses P. L. (2004). Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126, 1657–166410.1053/j.gastro.2004.03.013
    1. Collins S. M., Bercik P. (2009). The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003–201410.1053/j.gastro.2009.01.075
    1. Cryan J. F., Valentino R. J., Lucki I. (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29, 547–56910.1016/j.neubiorev.2005.03.008
    1. Dantzer R., O’Connor J. C., Freund G. G., Johnson R. W., Kelley K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–5610.1038/nrn2297
    1. Dautzenberg F. M., Higelin J., Wille S., Brauns O. (2004). Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant. Regul. Pept. 121, 89–9710.1016/j.regpep.2004.04.009
    1. Davis K. D., Pope G., Chen J., Kwan C. L., Crawley A. P., Diamant N. E. (2008). Cortical thinning in IBS: implications for homeostatic, attention, and pain processing. Neurology 70, 153–15410.1212/01.wnl.0000295509.30630.10
    1. Dinan T. G., Clarke G., Quigley E. M., Scott L. V., Shanahan F., Cryan J., Cooney J., Keeling P. W. (2008). Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol. 103, 2570–257610.1111/j.1572-0241.2008.01871.x
    1. Dinan T. G., Quigley E. M., Ahmed S. M., Scully P., O’Brien S., O’Mahony L., O’Mahony S., Shanahan F., Keeling P. W. (2006). Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130, 304–31110.1053/j.gastro.2005.11.033
    1. Dorn S. D., Palsson O. S., Thiwan S. I., Kanazawa M., Clark W. C., van Tilburg M. A., Drossman D. A., Scarlett Y., Levy R. L., Ringel Y., Crowell M. D., Olden K. W., Whitehead W. E. (2007). Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 56, 1202–120910.1136/gut.2006.117390
    1. Drossman D. A. (1998). Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom. Med. 60, 258–267
    1. Drossman D. A., Camilleri M., Mayer E. A., Whitehead W. E. (2002). AGA technical review on irritable bowel syndrome. Gastroenterology 123, 2108–213110.1053/gast.2002.37095
    1. Drossman D. A., Creed F. H., Olden K. W., Svedlund J., Toner B. B., Whitehead W. E. (1999). Psychosocial aspects of the functional gastrointestinal disorders. Gut 45(Suppl. 2), II25–II3010.1136/gut.45.2008.ii25
    1. Drossman D. A., Danilewitz M., Naesdal J., Hwang C., Adler J., Silberg D. G. (2008). Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am. J. Gastroenterol. 103, 2562–256910.1111/j.1572-0241.2008.02115.x
    1. Drossman D. A., Dumitrascu D. L. (2006). Rome III new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 15, 237–241
    1. Drossman D. A., Whitehead W. E., Toner B. B., Diamant N., Hu Y. J., Bangdiwala S. I., Jia H. (2000). What determines severity among patients with painful functional bowel disorders? Am. J. Gastroenterol. 95, 974–98010.1111/j.1572-0241.2000.01936.x
    1. Dunlop S. P., Coleman N. S., Blackshaw E., Perkins A. C., Singh G., Marsden C. A., Spiller R. C. (2005). Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 3, 349–35710.1016/S1542-3565(04)00726-8
    1. Elsenbruch S., Lucas A., Holtmann G., Haag S., Gerken G., Riemenschneider N., Langhorst J., Kavelaars A., Heijnen C. J., Schedlowski M. (2006). Public speaking stress-induced neuroendocrine responses and circulating immune cell redistribution in irritable bowel syndrome. Am. J. Gastroenterol. 101, 2300–230710.1111/j.1572-0241.2006.00837.x
    1. Engel G. L. (1977). The need for a new medical model: a challenge for biomedicine. Science 196, 129–13610.1126/science.847460
    1. Feldman S., Weidenfeld J. (1998). The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res. Bull. 45, 389–39310.1016/S0361-9230(97)00384-5
    1. Fichna J., Schicho R., Janecka A., Zjawiony J. K., Storr M. (2009). Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect. 22, 383–39210.1358/dnp.2009.22.7.1400219
    1. Ford A. C., Talley N. J., Schoenfeld P. S., Quigley E. M., Moayyedi P. (2009). Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58, 367–37810.1136/gut.2008.163162
    1. Fukudo S. (2007). Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J. Gastroenterol. 42(Suppl. 17), 48–5110.1007/s00535-006-1942-7
    1. Fukudo S., Kanazawa M. (2011). Gene, environment, and brain-gut interactions in irritable bowel syndrome. J. Gastroenterol. Hepatol. 26(Suppl. 3), 110–11510.1111/j.1440-1746.2011.06631.x
    1. Fukudo S., Nomura T., Hongo M. (1998). Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42, 845–84910.1136/gut.42.6.845
    1. Gaman A., Kuo B. (2008). Neuromodulatory processes of the brain-gut axis. Neuromodulation 11, 249–25910.1111/j.1525-1403.2008.00172.x
    1. Garvin B., Wiley J. W. (2008). The role of serotonin in irritable bowel syndrome: implications for management. Curr. Gastroenterol. Rep. 10, 363–36810.1007/s11894-008-0070-3
    1. Gershon M. D., Tack J. (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132, 397–41410.1053/j.gastro.2006.11.002
    1. Greco B., Allegretto E. A., Tetel M. J., Blaustein J. D. (2001). Coexpression of ER beta with ER alpha and progestin receptor proteins in the female rat forebrain: effects of estradiol treatment. Endocrinology 142, 5172–518110.1210/en.142.12.5172
    1. Greenwood-Van M. B., Gibson M., Gunter W., Shepard J., Foreman R., Myers D. (2001). Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain Res. 893, 135–14210.1016/S0006-8993(00)03305-9
    1. Gros D. F., Antony M. M., McCabe R. E., Swinson R. P. (2009). Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J. Anxiety Disord. 23, 290–29610.1016/j.janxdis.2008.08.004
    1. Grover M., Drossman D. A. (2011). Centrally acting therapies for irritable bowel syndrome. Gastroenterol. Clin. North Am. 40, 183–20610.1016/j.gtc.2010.12.003
    1. Grundmann O., Yoon S. L., Moshiree B. (2010). Current developments for the diagnosis and treatment of irritable bowel syndrome. Curr. Pharm. Des. 16, 3638–364510.2174/138161210794079227
    1. Gue M., Junien J. L., Bueno L. (1991). Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology 100, 964–970
    1. Gustafsson J. K., Greenwood-Van M. B. (2011). Amygdala activation by corticosterone alters visceral and somatic pain in cycling female rats. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G1080–G108510.1152/ajpgi.00349.2010
    1. Gwee K. A., Leong Y. L., Graham C., McKendrick M. W., Collins S. M., Walters S. J., Underwood J. E., Read N. W. (1999). The role of psychological and biological factors in postinfective gut dysfunction. Gut 44, 400–40610.1136/gut.44.3.400
    1. Hall G. B., Kamath M. V., Collins S., Ganguli S., Spaziani R., Miranda K. L., Bayati A., Bienenstock J. (2010). Heightened central affective response to visceral sensations of pain and discomfort in IBS. Neurogastroenterol. Motil. 22, 276–e8010.1111/j.1365-2982.2009.01436.x
    1. Herman J. P., Figueiredo H., Mueller N. K., Ulrich-Lai Y., Ostrander M. M., Choi D. C., Cullinan W. E. (2003). Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24:7.10.1016/j.yfrne.2003.07.001
    1. Houghton L. A., Lea R., Jackson N., Whorwell P. J. (2002). The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 50, 471–47410.1136/gut.50.4.471
    1. Hsu S. Y., Hsueh A. J. (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7, 605–61110.1038/87936
    1. Ibeakanma C., Ochoa-Cortes F., Miranda-Morales M., McDonald T., Spreadbury I., Cenac N., Ibeakanma C., Ochoa-Cortes F., Miranda-Morales M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D., Vanner S., Bunnett N., Vergnolle N., Vanner S. (2011). Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 141, 2098–210810.1053/j.gastro.2011.08.006
    1. Izzo A. A., Sharkey K. A. (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 126, 21–3810.1016/j.pharmthera.2009.12.005
    1. Jarcho J. M., Chang L., Berman M., Suyenobu B., Naliboff B. D., Lieberman M. D., Ameen V. Z., Mandelkern M. A., Mayer E. A. (2008). Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment. Pharmacol. Ther. 28, 344–35210.1111/j.1365-2036.2008.03721.x
    1. Jarrett M. E., Burr R. L., Cain K. C., Hertig V., Weisman P., Heitkemper M. M. (2003). Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Dig. Dis. Sci. 48, 386–39410.1023/A:1021904216312
    1. John C. D., Buckingham J. C. (2003). Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Curr. Opin. Pharmacol. 3, 78–8410.1016/S1471-4892(02)00009-7
    1. Johnson A. C., Myers B., Lazovic J., Towner R., Greenwood-Van M. B. (2010). Brain activation in response to visceral stimulation in rats with amygdala implants of corticosterone: an FMRI study. PLoS ONE 5, e8573.10.1371/journal.pone.0015109
    1. Kane S. V., Sable K., Hanauer S. B. (1998). The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am. J. Gastroenterol. 93, 1867–187210.1111/j.1572-0241.1998.540_i.x
    1. Kennedy P. J., Clarke G., Quigley E. M., Groeger J. A., Dinan T. G., Cryan J. F. (2012). Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci. Biobehav. Rev. 36, 310–34010.1016/j.neubiorev.2011.07.001
    1. Khasar S. G., Burkham J., Dina O. A., Brown A. S., Bogen O., Alessandri-Haber N., Green P. G., Reichling D. B., Levine J. D. (2008). Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J. Neurosci. 28, 5721–573010.1523/JNEUROSCI.0256-08.2008
    1. Kilpatrick L. A., Ornitz E., Ibrahimovic H., Treanor M., Craske M., Nazarian M., Kilpatrick L. A., Ornitz E., Ibrahimovic H., Treanor M., Craske M., Nazarian M., Labus J. S., Mayer E. A., Naliboff B. D. (2010). Sex-related differences in prepulse inhibition of startle in irritable bowel syndrome (IBS). Biol. Psychol. 84, 272–27810.1016/j.biopsycho.2010.02.012
    1. Kirby L. G., Rice K. C., Valentino R. J. (2000). Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22, 148–16210.1016/S0893-133X(99)00093-7
    1. Kostich W. A., Chen A., Sperle K., Largent B. L. (1998). Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol. Endocrinol. 12, 1077–108510.1210/me.12.8.1077
    1. Kozlowski C. M., Green A., Grundy D., Boissonade F. M., Bountra C. (2000). The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 46, 474–48010.1136/gut.46.4.474
    1. Kwan C. L., Diamant N. E., Pope G., Mikula K., Mikulis D. J., Davis K. D. (2005). Abnormal forebrain activity in functional bowel disorder patients with chronic pain. Neurology 65, 1268–127710.1212/
    1. Labus J. S., Naliboff B. N., Fallon J., Berman S. M., Suyenobu B., Bueller J. A., Mandelkern M., Mayer E. A. (2008). Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 41, 1032–104310.1016/j.neuroimage.2008.03.009
    1. Lackner J. M., Lou C. M., Mertz H. R., Wack D. S., Katz L. A., Krasner S. S., Firth R., Mahl T. C., Lockwood A. H. (2006). Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav. Res. Ther. 44, 621–63810.1016/j.brat.2005.05.002
    1. Larauche M., Mulak A., Tache Y. (2012). Stress and visceral pain: from animal models to clinical therapies. Exp. Neurol. 233, 49–6710.1016/j.expneurol.2011.04.020
    1. Lawal A., Kern M., Sidhu H., Hofmann C., Shaker R. (2006). Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 130, 26–3310.1053/j.gastro.2005.10.020
    1. Lee S. Y., Kim J. H., Sung I. K., Park H. S., Jin C. J., Choe W. H., Kwon S. Y., Lee C. H., Choi K. W. (2007). Irritable bowel syndrome is more common in women regardless of the menstrual phase: a Rome II-based survey. J. Korean Med. Sci. 22, 851–85410.3346/jkms.2007.22.5.912
    1. Lembo T., Plourde V., Shui Z., Fullerton S., Mertz H., Tache Y., Sytnik B., Munakata J., Mayer E. (1996). Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol. Motil. 8, 9–1810.1111/j.1365-2982.1996.tb00237.x
    1. Lewis K., Li C., Perrin M. H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T. M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P. E., Vale W. W. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98, 7570–757510.1073/pnas.081075898
    1. Lindstrom E., Ravnefjord A., Brusberg M., Hjorth S., Larsson H., Martinez V. (2009). The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats. J. Pharmacol. Exp. Ther. 329, 1048–105510.1124/jpet.109.152330
    1. Lowry C. A., Moore F. L. (2006). Regulation of behavioral responses by corticotropin-releasing factor. Gen. Comp. Endocrinol. 146, 19–2710.1016/j.ygcen.2005.12.006
    1. Lukkes J. L., Forster G. L., Renner K. J., Summers C. H. (2008). Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur. J. Pharmacol. 578, 185–19310.1016/j.ejphar.2007.09.024
    1. Mach T. (2004). The brain-gut axis in irritable bowel syndrome – clinical aspects. Med. Sci. Monit. 10, RA125–RA131
    1. Manini M. L., Camilleri M., Goldberg M., Sweetser S., McKinzie S., Burton D., Wong S., Kitt M. M., Li Y. P., Zinsmeister A. R. (2010). Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol. Motil. 22, 42–48
    1. Martinez V., Tache Y. (2006). CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr. Pharm. Des. 12, 4071–408810.2174/138161206778743637
    1. Martinez V., Wang L., Rivier J., Grigoriadis D., Tache Y. (2004). Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J. Physiol. (Lond.) 556(Pt 1), 221–23410.1113/jphysiol.2003.059659
    1. Mayer E. A., Collins S. M. (2002). Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122, 2032–204810.1053/gast.2002.33584
    1. Mayer E. A., Naliboff B., Lee O., Munakata J., Chang L. (1999). Review article: gender-related differences in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 13(Suppl. 2), 65–6910.1046/j.1365-2036.1999.00008.x
    1. Mayer E. A., Naliboff B. D., Craig A. D. (2006). Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 131, 1925–194210.1053/j.gastro.2006.10.026
    1. McEwen B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873–90410.1152/physrev.00041.2006
    1. McKernan D. P., Gaszner G., Quigley E. M., Cryan J. F., Dinan T. G. (2011). Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 33, 1045–105210.1111/j.1365-2036.2011.04624.x
    1. McKernan D. P., Nolan A., Brint E. K., O’Mahony S. M., Hyland N. P., Cryan J. F., Dinan T. G. (2009). Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS ONE 4, e8226.10.1371/journal.pone.0008226
    1. Mertz H., Morgan V., Tanner G., Pickens D., Price R., Shyr Y., Kessler R. (2000). Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 118, 842–84810.1016/S0016-5085(00)85511-0
    1. Meuser T., Pietruck C., Gabriel A., Xie G. X., Lim K. J., Pierce P. P. (2002). 5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci. 71, 2279–228910.1016/S0024-3205(02)02011-8
    1. Million M., Grigoriadis D. E., Sullivan S., Crowe P. D., McRoberts J. A., Zhou H., Saunders P. R., Maillot C., Mayer E. A., Taché Y. (2003). A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res. 985, 32–4210.1016/S0006-8993(03)03027-0
    1. Milner T. A., Lubbers L. S., Alves S. E., McEwen B. S. (2008). Nuclear and extranuclear estrogen binding sites in the rat forebrain and autonomic medullary areas. Endocrinology 149, 3306–331210.1210/en.2008-0307
    1. Moreau J. L., Kilpatrick G., Jenck F. (1997). Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport 8, 1697–170110.1097/00001756-199705060-00027
    1. Morin S. M., Ling N., Liu X. J., Kahl S. D., Gehlert D. R. (1999). Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience 92, 281–29110.1016/S0306-4522(98)00732-5
    1. Mulak A., Bonaz B. (2004). Irritable bowel syndrome: a model of the brain-gut interactions. Med. Sci. Monit. 10, RA55–RA62
    1. Mulak A., Paradowski L. (2006). Effect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients. World J. Gastroenterol. 12, 1591–1596
    1. Myers B., Greenwood-Van M. B. (2007). Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1622–G162910.1152/ajpgi.00080.2007
    1. Myers B., Greenwood-Van M. B. (2009). Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. Front. Neurosci. 3:47.10.3389/neuro.21.002.2009
    1. Myers B., Greenwood-Van M. B. (2010). Elevated corticosterone in the amygdala leads to persistent increases in anxiety-like behavior and pain sensitivity. Behav. Brain Res. 214, 465–46910.1016/j.bbr.2010.05.049
    1. Myers B., Schulkin J., Greenwood-Van M. B. (2011). Sex steroids localized to the amygdala increase pain responses to visceral stimulation in rats. J. Pain. 12, 486–49410.1016/j.jpain.2010.10.007
    1. Naliboff B. D., Berman S., Chang L., Derbyshire S. W., Suyenobu B., Vogt B. A., Mandelkern M., Mayer E. A. (2003). Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 124, 1738–174710.1016/S0016-5085(03)00400-1
    1. Naliboff B. D., Derbyshire S. W., Munakata J., Berman S., Mandelkern M., Chang L., Mayer E. A. (2001). Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom. Med. 63, 365–375
    1. Niddam D. M., Tsai S. Y., Lu C. L., Ko C. W., Hsieh J. C. (2011). Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. Am. J. Gastroenterol. 106, 1503–151110.1038/ajg.2011.120
    1. Ohman L., Simren M. (2010). Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 7, 163–17310.1038/nrgastro.2010.4
    1. O’Mahony S. M., Bulmer D. C., Coelho A. M., Fitzgerald P., Bongiovanni C., Lee K., Winchester W., Dinan T. G., Cryan J. F. (2010a). 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol. Motil. 22, 573–578, e124.10.1111/j.1365-2982.2009.01432.x
    1. O’Mahony S. M., Bulmer D. C., Coelho A. M., Fitzgerald P., Bongiovanni C., Lee K., Winchester W., Dinan T. G., Cryan J. F. (2010b). 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol. Motil. 22, 573–578, e124.10.1111/j.1365-2982.2009.01432.x
    1. O’Mahony S. M., Hyland N. P., Dinan T. G., Cryan J. F. (2011). Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl.) 214, 71–8810.1007/s00213-010-2010-9
    1. Owens M. J., Nemeroff C. B. (1993). The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found. Symp. 172, 296–308
    1. Pandey S. C., Zhang H., Roy A., Misra K. (2006). Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors. J. Neurosci. 26, 8320–833110.1523/JNEUROSCI.4988-05.2006
    1. Penalva R. G., Flachskamm C., Zimmermann S., Wurst W., Holsboer F., Reul J. M., Linthorst A. C. (2002). Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: an in vivo microdialysis study in mutant mice. Neuroscience 109, 253–26610.1016/S0306-4522(01)00475-4
    1. Philpott H., Gibson P., Thien F. (2011). Irritable bowel syndrome – an inflammatory disease involving mast cells. Asia Pac. Allergy 1, 36–4210.5415/apallergy.2011.1.1.36
    1. Piche M., Bouin M., Arsenault M., Poitras P., Rainville P. (2011). Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes. Neuroscience 195, 166–17510.1016/j.neuroscience.2011.08.040
    1. Prado W. A., Roberts M. H. (1985). An assessment of the antinociceptive and aversive effects of stimulating identified sites in the rat brain. Brain Res. 340, 219–22810.1016/0006-8993(85)90917-5
    1. Price M. L., Curtis A. L., Kirby L. G., Valentino R. J., Lucki I. (1998). Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18, 492–50210.1016/S0893-133X(97)00197-8
    1. Rapps N., van Oudenhove L., Enck P., Aziz Q. (2008). Brain imaging of visceral functions in healthy volunteers and IBS patients. J. Psychosom. Res. 64, 599–60410.1016/j.jpsychores.2008.02.018
    1. Redgate E. S., Fahringer E. E. (1973). A comparison of the pituitary adrenal activity elicited by electrical stimulation of preoptic, amygdaloid and hypothalamic sites in the rat brain. Neuroendocrinology 12, 334–34310.1159/000122182
    1. Ren T. H., Wu J., Yew D., Ziea E., Lao L., Leung W. K., Berman B., Hu P. J., Sung J. J. (2007). Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G849–G85610.1152/ajpgi.00400.2006
    1. Reyes T. M., Lewis K., Perrin M. H., Kunitake K. S., Vaughan J., Arias C. A., Hogenesch J. B., Gulyas J., Rivier J., Vale W. W., Sawchenko P. E. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98, 2843–284810.1073/pnas.051626398
    1. Ribeiro S. C., Kennedy S. E., Smith Y. R., Stohler C. S., Zubieta J. K. (2005). Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1264–128010.1016/j.pnpbp.2005.08.011
    1. Ringel Y. (2002). Brain research in functional gastrointestinal disorders. J. Clin. Gastroenterol. 35(1 Suppl.), S23–S2510.1097/00004836-200207001-00003
    1. Ringel Y., Drossman D. A., Leserman J. L., Suyenobu B. Y., Wilber K., Lin W., Whitehead W. E., Naliboff B. D., Berman S., Mayer E. A. (2008). Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 134, 396–40410.1053/j.gastro.2007.11.011
    1. Rosas-Ballina M., Tracey K. J. (2009). The neurology of the immune system: neural reflexes regulate immunity. Neuron 64, 28–3210.1016/j.neuron.2009.09.039
    1. Sagami Y., Shimada Y., Tayama J., Nomura T., Satake M., Endo Y., Shoji T., Karahashi K., Hongo M., Fukudo S. (2004). Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53, 958–96410.1136/gut.2003.018911
    1. Saito K., Kanazawa M., Fukudo S. (2002). Colorectal distention induces hippocampal noradrenaline release in rats: an in vivo microdialysis study. Brain Res. 947, 146–14910.1016/S0006-8993(02)03007-X
    1. Salari P., Abdollahi M. (2011). Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J. Gastroenterol. 17, 4251–425710.3748/wjg.v17.i38.4251
    1. Sandler R. S., Everhart J. E., Donowitz M., Adams E., Cronin K., Goodman C., Gemmen E., Shah S., Avdic A., Rubin R. (2002). The burden of selected digestive diseases in the United States. Gastroenterology 122, 1500–151110.1053/gast.2002.32978
    1. Saunders P. R., Maillot C., Million M., Tache Y. (2002). Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion. Eur. J. Pharmacol. 435, 231–23510.1016/S0014-2999(01)01574-6
    1. Seminowicz D. A., Labus J. S., Bueller J. A., Tillisch K., Naliboff B. D., Bushnell M. C., Mayer E. A. (2010). Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 139, 48–5710.1053/j.gastro.2010.03.049
    1. Shepard J. D., Barron K. W., Myers D. A. (2003). Stereotaxic localization of corticosterone to the amygdala enhances hypothalamo-pituitary-adrenal responses to behavioral stress. Brain Res. 963, 203–21310.1016/S0006-8993(02)03978-1
    1. Sivarao D. V., Newberry K., Lodge N. J. (2004). Effect of the 5HT1A receptor partial agonist buspirone on colorectal distension-induced pseudoaffective and behavioral responses in the female Wistar rat. Eur. J. Pharmacol. 494, 23–2910.1016/j.ejphar.2004.04.034
    1. Slack S. E., Pezet S., McMahon S. B., Thompson S. W., Malcangio M. (2004). Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur. J. Neurosci. 20, 1769–177810.1111/j.1460-9568.2004.03656.x
    1. Slawecki C. J., Somes C., Rivier J. E., Ehlers C. L. (1999). Neurophysiological effects of intracerebroventricular administration of urocortin. Peptides 20, 211–21810.1016/S0196-9781(98)00160-0
    1. Smith G. W., Aubry J. M., Dellu F., Contarino A., Bilezikjian L. M., Gold L. H., Chen R., Marchuk Y., Hauser C., Bentley C. A., Sawchenko P. E., Koob G. F., Vale W., Lee K. F. (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20, 1093–110210.1016/S0896-6273(00)80504-8
    1. Southwick S. M., Bremner J. D., Rasmusson A., Morgan C. A., III, Arnsten A., Charney D. S. (1999). Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol. Psychiatry 46, 1192–120410.1016/S0006-3223(99)00107-9
    1. Spaziani R., Bayati A., Redmond K., Bajaj H., Mazzadi S., Bienenstock J., Collins S. M., Kamath M. V. (2008). Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol. Motil. 20, 336–34210.1111/j.1365-2982.2007.01042.x
    1. Spiller R. (2007). Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol. Motil. 19(Suppl. 2), 25–3110.1111/j.1365-2982.2007.00965.x
    1. Spiller R., Garsed K. (2009). Infection, inflammation, and the irritable bowel syndrome. Dig. Liver Dis. 41, 844–84910.1016/j.dld.2009.07.007
    1. Sweetser S., Camilleri M., Linker Nord S. J., Burton D. D., Castenada L., Croop R., Tong G., Dockens R., Zinsmeister A. R. (2009). Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1299–G130610.1152/ajpgi.00011.2009
    1. Tache Y., Brunnhuber S. (2008). From Hans Selye’s discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. Ann. N. Y. Acad. Sci. 1148, 29–4110.1196/annals.1410.007
    1. Tache Y., Kiank C., Stengel A. (2009). A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr. Gastroenterol. Rep. 11, 270–27710.1007/s11894-009-0040-4
    1. Tache Y., Martinez V., Million M., Maillot C. (2002). Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. 168(Suppl. 1), 16–22
    1. Tache Y., Martinez V., Wang L., Million M. (2004). CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol. 141, 1321–133010.1038/sj.bjp.0705760
    1. Tack J., Broekaert D., Fischler B., van Oudenhove L., Gevers A. M., Janssens J. (2006). A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55, 1095–110310.1136/gut.2004.060426
    1. Tack J., Coulie B., Wilmer A., Andrioli A., Janssens J. (2000). Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 46, 468–47310.1136/gut.46.4.468
    1. Takeuchi O., Akira S. (2010). Pattern recognition receptors and inflammation. Cell 140, 805–82010.1016/j.cell.2010.01.022
    1. Thompson W. G., Heaton K. W., Smyth G. T., Smyth C. (2000). Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 46, 78–8210.1136/gut.46.1.78
    1. Tillisch K., Labus J., Nam B., Bueller J., Smith S., Suyenobu B., Siffert J., McKelvy J., Naliboff B., Mayer E. (2012). Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment. Pharmacol. Ther. 35, 360–36710.1111/j.1365-2036.2011.04958.x
    1. Tillisch K., Mayer E. A., Labus J. S. (2011). Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 140, 91–10010.1053/j.gastro.2010.07.053
    1. Tillisch K., Mayer E. A., Labus J. S., Stains J., Chang L., Naliboff B. D. (2005). Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 54, 1396–140110.1136/gut.2004.058685
    1. Tjong Y. W., Ip S. P., Lao L., Wu J., Fong H. H., Sung J. J., Berman B., Che C. T. (2010). Neonatal maternal separation elevates thalamic corticotrophin releasing factor type 1 receptor expression response to colonic distension in rat. Neuro Endocrinol. Lett. 31, 215–220
    1. Toner B. B., Segal Z. V., Emmott S., Myran D., Ali A., DiGasbarro I., Stuckless N. (1998). Cognitive-behavioral group therapy for patients with irritable bowel syndrome. Int. J. Group Psychother. 48, 215–243
    1. Trimble N., Johnson A. C., Foster A., Greenwood-Van M. B. (2007). Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol. Motil. 19, 754–76010.1111/j.1365-2982.2007.00951.x
    1. Tyler K., Moriceau S., Sullivan R. M., Greenwood-Van M. B. (2007). Long-term colonic hypersensitivity in adult rats induced by neonatal unpredictable vs predictable shock. Neurogastroenterol. Motil. 19, 761–76810.1111/j.1365-2982.2007.00955.x
    1. Vale W., Spiess J., Rivier C., Rivier J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213, 1394–139710.1126/science.6267699
    1. Valentino R. J., Commons K. G. (2005). Peptides that fine-tune the serotonin system. Neuropeptides 39, 1–810.1016/j.npep.2004.09.005
    1. Vanhoenacker P., Haegeman G., Leysen J. E. (2000). 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol. Sci. 21, 70–7710.1016/S0165-6147(99)01432-7
    1. Venkova K., Johnson A. C., Myers B., Greenwood-Van M. B. (2010). Exposure of the amygdala to elevated levels of corticosterone alters colonic motility in response to acute psychological stress. Neuropharmacology 58, 1161–116710.1016/j.neuropharm.2010.02.012
    1. Vera-Portocarrero L. P., Ossipov M. H., King T., Porreca F. (2008). Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 135, 1369–137810.1053/j.gastro.2008.06.085
    1. Vetter D. E., Li C., Zhao L., Contarino A., Liberman M. C., Smith G. W., Marchuk Y., Koob G. F., Heinemann S. F., Vale W., Lee K. F. (2002). Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. 31, 363–369
    1. Videlock E. J., Adeyemo M., Licudine A., Hirano M., Ohning G., Mayer M., Mayer E. A., Chang L. (2009). Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology 137, 1954–196210.1053/j.gastro.2009.08.058
    1. Wilder-Smith C. H., Schindler D., Lovblad K., Redmond S. M., Nirkko A. (2004). Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 53, 1595–160110.1136/gut.2003.028514
    1. Winston J. H., Xu G. Y., Sarna S. K. (2010). Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology 138, 294–30410.1016/S0016-5085(10)63555-X
    1. Yu Y. B., Zuo X. L., Zhao Q. J., Chen F. X., Yang J., Dong Y. Y., Wang P., Li Y.-Q. (2012). Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 61, 685–69410.1136/gutjnl-2011-300265
    1. Zisterer D. M., Williams D. C. (1997). Peripheral-type benzodiazepine receptors. Gen. Pharmacol. 29, 305–31410.1016/S0306-3623(96)00473-9
    1. Zou B. C., Dong L., Wang Y., Wang S. H., Cao M. B. (2007). Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Chin. Med. J. 120, 2069–2074

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa